Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflapegrastim Same-Day Dosing in Early-Stage Breast Cancer
NCT04187898Phase 1Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Mar 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esketamine in neutropenia (4 arms), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Time to Recovery of Absolute Neutrophil Count (ANC) From Nadir to >=1.5x10^9/L in Cycle 1. Started Mar 2020; status: completed.
02
Drugs
esketamine
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT04187898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187898.